Heart Transplant Rejection: Pipeline Review (H1 2018) Featuring Astellas Pharma, Heat Biologics, Noxxon Pharma, and TxCell - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Oct 19, 2018--The “Heart Transplant Rejection - Pipeline Review, H1 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This latest Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Heart Transplant Rejection (Immunology) pipeline landscape.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Heart Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/c7qdk6/heart_transplant?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181019005209/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs,Immunosuppressive Drugs
INDUSTRY KEYWORD: SURGERY HEALTH CARDIOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 10/19/2018 06:06 AM/DISC: 10/19/2018 06:06 AM